Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | $124.12B | -232x | 2.05 | $483.26 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $66.99B | 15.3x | 1.51 | $625.60 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $43.45B | 58x | $60.21 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $35.40B | 41.4x | 0.13 | $583.51 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.4% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $30.77B | 22.9x | 8.3 | $174.37 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | $29.15B | -44.4x | -1.62 | $275.03 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.9% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $22.47B | -31.1x | 0.18 | $93.32 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.05B | 11.8x | 0.47 | $312.44 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.7% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $13.87B | -59.7x | -0.98 | $20.46 | 8.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $13.82B | 31.2x | 35.47 | $3.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $13.82B | 31.2x | 35.47 | $6.76 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $13.68B | 17.6x | 0.63 | $168.70 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.1% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $13.26B | -13x | 3.58 | $73.42 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.3% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.81B | 10.4x | 0.13 | $18.82 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.7% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.80B | 31.6x | 1 | $108.24 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.76B | -3x | -0.14 | $27.72 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.3% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.38B | 20.5x | 0.12 | $37.07 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.2% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.50B | 0.56 | $311.23 | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.24B | 58x | -1.99 | $58.38 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.06B | -22.1x | -0.96 | $152.15 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.9% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $8.65B | 102.8x | -1.35 | $40.03 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.28B | -7.9x | 0.02 | $44.56 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.17B | -7.8x | 0.23 | $49.94 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.7% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $7.66B | 744.1x | -7.9 | $149.28 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.42B | -15.1x | 1.63 | $335 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.43B | -9.6x | -1.6 | $34.60 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.12B | -34.1x | -0.54 | $33.24 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.02B | 25.3x | 0.21 | $62.47 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
TG | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.79B | 248.7x | 3.64 | $39.82 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.76B | -83.1x | -0.97 | $90.01 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.45B | 190.5x | 0.23 | $16.21 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.2% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.32B | 14.5x | 4.18 | $32.63 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.25B | 57.4x | 0.09 | $180.85 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.07B | -17.9x | 0.25 | $70.46 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.97B | -30.5x | 0.15 | $60.38 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.8% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.77B | -7.8x | -2.52 | $40.23 | 7.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.55B | -63.3x | 0.07 | $19.05 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.54B | -9.3x | 0.58 | $28.71 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.32B | -8.7x | -2.36 | $33.65 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SpringWorks | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.48B | -13.3x | -0.42 | $46.50 | 11% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.38B | -16.7x | 0.22 | $73.67 | 7.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.34B | -32.3x | 0.96 | $67.23 | 10.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.32B | -11x | 0.45 | $41.95 | 8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Rhythm Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.28B | -11.9x | 0.37 | $51.93 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ultragenyx | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.27B | -5.6x | -0.26 | $35.37 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | $3.07B | -12.2x | 0.62 | $32.54 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.98B | -12.6x | 1.23 | $43.07 | 8.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.96B | 10.8x | 0.03 | $48.20 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.2% Upside | Upgrade to Pro+ | |
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.95B | -8.4x | $31.39 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $2.93B | -7.8x | 0.07 | $34.21 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |